The Cooper Companies, Inc. (COO) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Tocqueville Asset Management’s 4.6‑hour‑old 13F filing shows a fresh purchase of 20,952 shares of The Cooper Companies (COO) for roughly $1.5 million, underscoring renewed confidence from a major institutional investor amid a broader uptick in medical‑device holdings. This inflow could tighten short‑term liquidity and signal a potential valuation reassessment as other hedge funds and asset managers expand positions. The earlier 19.9‑hour report indicates COO has cut its revenue growth outlook to 4.2%, reflecting softness in its vision‑care and women’s‑health lines, and highlights that recent capital investments have returned below the industry cost of capital. The company’s near‑term strategy now pivots to premium lens sales and fertility product launches, which may help offset the weaker top‑line forecast. The combination of institutional buying and a cautious growth outlook creates a mixed backdrop: the inflow may support the stock, while the lower growth projection could temper enthusiasm. Traders should watch how COO’s upcoming earnings address capital‑allocation efficiency and whether the premium lens and fertility initiatives deliver the expected lift. Additionally, monitor any further institutional purchases that could reinforce the liquidity narrative. Finally, keep an eye on the company’s guidance for the next quarter to gauge whether the execution focus translates into improved margins and cash flow.

COO|Company Info

Sector

Healthcare

Industry

Medical Instruments & Supplies

Exchange

NMS

Country

United States

Website

coopercos.com

Symbol

COO

Description

Cooper Companies, Inc. is a global medical device company primarily focused on two distinct segments: vision care and women's health. Through its CooperVision division, the company designs, manufactures, and distributes a comprehensive portfolio of contact lenses, addressing a range of vision impairments including astigmatism, presbyopia, and myopia. The CooperSurgical segment concentrates on fertility solutions, women's health devices, and related services, including hormone-free contraception and cryostorage options. Cooper Companies' products and services are marketed to a diverse network of distributors, healthcare professionals, and institutions, encompassing both independent and corporate entities. Founded in 1958, the company leverages its established presence and product diversity to serve the needs of eye care and women's health markets.

COO|Earnings Snapshot

Earnings Summary

Cooper Companies, Inc. is a global medical device firm operating primarily in vision care through its CooperVision division and in women’s health via CooperSurgical, offering contact lenses and fertility solutions to a broad distributor network. The company’s dual‑segment model positions it within the competitive medical instruments and supplies sector, where product innovation and regulatory compliance drive growth. In the most recent quarters, Q1 2025 and Q2 2025, the company posted EPS of $0.96 and $1.10, respectively, both beating analyst estimates of $0.92922 and $1.06756, while revenue rose from $1.0023 billion to $1.0603 billion, a 5.8% increase; Q3 2025 continued the trend with EPS of $1.15 versus an estimate of $1.11337 and revenue of $1.0652 billion, a modest 0.5% rise. Compared to the prior two quarters (Q4 2024 and Q1 2025), the company accelerated its EPS growth from 0.92 to 1.15, a 25% YoY lift, and maintained a consistent pattern of beating earnings estimates in each of the last four quarters, while revenue growth has been steady but modest. Historically, Cooper has shown a YoY revenue growth trajectory of roughly 4–6% over the past three years, with EPS consistently exceeding expectations, indicating disciplined cost management and pricing power; however, the company’s revenue growth has occasionally plateaued, as seen in Q3 2025’s 0.5% rise. Recent analyst upgrades—Citigroup, Argus Research, and Zacks—have lifted price targets to $80–$82, citing expected higher revenue and margin expansion, and the company’s upcoming Q3 2026 earnings release on September 9 will be a key catalyst for confirming these expectations; investors should watch for guidance on revenue mix, margin dynamics, and any cost‑control initiatives that could validate the optimistic outlook. Key watch points for the next quarter include monitoring the company’s guidance on revenue growth versus the $1.07 billion estimate, the impact of commodity price swings on margins, and any commentary on new product launches or regulatory developments that could influence the earnings trajectory.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q4'25	$1.03	-	-
Q2'26	$1.11	$1.21	+9.3%
Q1'26	$1.04	$1.10	+5.7%
Q3'25	$1.11	$1.15	+3.3%
Q2'25	$1.07	$1.10	+3.0%
Q1'25	$0.93	$0.96	+3.3%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q4'25	$1.0B	-	-
Q2'26	$1.1B	$1.1B	+1.6%
Q1'26	$1.0B	$1.0B	-1.2%
Q3'25	-	$1.1B	-
Q2'25	-	$1.1B	-
Q1'25	-	$1.0B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

COO Stock Snapshot

COO is currently trading at $73.92, giving The Cooper Companies, Inc. a market cap of 15.03B and a P/E ratio of 63.7. Today's range spans $73.92–$76.20, with shares opening at $75.42 and moving down $1.88 (2.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 69/100.

Over the past year COO has traded between $58.89 and $89.83 - the current price is +25.5% off the 52-week low and -17.7% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $81.50 (range $66.00–$92.00), implying upside of +10.3%.

Relative strength is the story for The Cooper Companies, Inc. (COO) in Healthcare right now. Technical score 82/100 (BUY), sentiment bullish at 69/100, price $73.92 (in the middle of its 52-week range). The current P/E ratio stands at 63.7. The 15.03B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $58.89–$89.83.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (69/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $73.92 (in the middle of its 52-week range), COO's position within the $58.89–$89.83 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

COO Competitive Positioning

The Cooper Companies, Inc. (COO) is tracked alongside these names in Medical Instruments & Supplies on DailyIQ.

News Sentiment Analysis

Sentiment gathered from recent headlines

69/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

Tocqueville Asset Management L.P. disclosed a new 20,952‑share purchase of The Cooper Companies, Inc. (COO) in its latest 13F filing, valuing the stake at roughly $1.5 million. The acquisition signals confidence from a prominent institutional investor amid a broader trend of increased buying by hedge funds and asset managers in the medical device sector. The move may prompt a review of COO’s valuation and liquidity, as other major investors are also expanding positions. Traders should monitor how this institutional inflow affects short‑term price dynamics and whether it precedes a broader rally in the company’s shares.

What did this article say?

Cooper Companies (COO) now projects a 4.2% revenue growth, lower than previous years, signaling potential demand softness in its vision care and women's health segments. Past capital investments have yielded returns below the industry cost of capital, raising questions about management’s deployment efficiency. The company’s near‑term focus shifts to executing premium lens sales and fertility product launches to drive incremental revenue. Investors should monitor how COO addresses capital allocation and execution risk in upcoming earnings releases.

What did this article say?

Cooper Companies’ shares trade above fair value, yet a DCF model suggests upside while earnings multiples flag overvaluation. The company’s five‑year decline of 31.3% leaves long‑term holders underwater despite recent gains. Market confidence hinges on future cash‑flow conversion; any shortfall or increased capital needs could erode the premium. The valuation debate centers on whether intrinsic value or market multiples better guide pricing.

What did this article say?

CooperCompanies (COO) has seen its shares decline to $75.74 over the past six months, reflecting a 9.5% loss amid a broader market rally. The company’s annualized revenue growth of 6.5% over the last two years falls below its five‑year trend, raising concerns about demand deceleration. Wall Street forecasts project modest revenue growth, suggesting limited upside potential in the near term. Investors should weigh the risk of continued revenue slowdown against the attractive entry price.

What did this article say?

Citigroup lifts Cooper Companies price target to $80 while maintaining a neutral rating, suggesting modest upside potential for the stock.

What did this article say?

The Cooper Companies (COO) received a Zacks Rank #2 (Buy) upgrade, reflecting growing optimism about its earnings prospects. Analysts anticipate higher revenue and improved margins in the upcoming quarter. The upgrade suggests potential upside for the stock, but investors should monitor earnings guidance and competitive dynamics in the healthcare services sector.

What did this article say?

The piece contrasts COO and MMSI, focusing on valuation multiples, earnings growth, and dividend yields. COO's lower P/E and higher dividend yield make it attractive for income-focused investors, while MMSI offers higher growth potential but at a premium. Traders should monitor upcoming earnings releases and any changes in dividend policy that could shift the valuation balance.

What did this article say?

Argus Research has raised its target price for COO to $82, citing stronger earnings guidance and margin expansion. The upgrade reflects confidence in the company’s ability to capitalize on rising commodity prices and cost efficiencies. Traders should monitor COO’s upcoming earnings release and commodity price movements for confirmation of the positive outlook.

What did this article say?

Cooper Companies (COO) announced that its third‑quarter 2026 financial results will be released on Wednesday, September 9 at 4:15 PM ET. The company will follow the earnings call with a conference call at 5:00 PM ET to discuss the results and other corporate developments. Investors should note the timing relative to the company’s guidance cycle and the potential impact of any new product launches or regulatory updates disclosed during the call.